People in drug discovery often talk about cheap experiments with a faint tone of apology.

Cheap assay. Rough proxy. Easy analogue. Fast route. Lower-fidelity signal.

The implication is that these are compromises. Useful only until the serious measurements arrive.

That view is too static.

When the learning loop is the bottleneck, cheap experiments can be an advantage in their own right.

A slow perfect experiment can lose to a fast imperfect one

This is not because the perfect experiment stopped being informative.

It is because timing changes value.

An elegant, expensive assay that arrives six weeks late may tell you less, in practical terms, than a rougher measurement that lands tomorrow and changes which ten compounds get made next. A high-fidelity readout on one heroic molecule may contribute less to project progress than a batch of cheaper measurements that reshape local priors across the whole series.

The field is still too tempted by purity. It assumes the better experiment is the one with the cleaner signal. In deployment, the better experiment is often the one that sharpens the next decision soon enough to matter.

Cheap data often buys model improvement faster

This matters even more once you stop thinking only about the current compound and start thinking about the model you want next week.

A cheap assay, run broadly, can map a local landscape faster than a sparse expensive panel ever will. Easy chemistry can generate enough nearby analogues to reveal the real contour of a series. Rough measurements can expose which region deserves expensive follow-up and which one should be abandoned immediately.

That means cheap experiments are not just a cost-saving measure.

They are a way to manufacture local training signal at a speed expensive experiments cannot match.

Easy-to-make compounds are sensors

This is one of the reasons medicinal chemistry can look “conservative” from the outside.

Teams often lean on chemistry that is already in hand because it enables fast, repeated probes of the space. Those probes are not always attempts to discover the final molecule. Often they are sensors. They reveal where potency bends, where permeability breaks, where a liability is vector-specific, where a route opens a family versus a one-off.

From a static optimisation perspective, that can look pedestrian.

From a closed-loop perspective, it is exactly how a project learns quickly.

Noise is not fatal if the loop is fast enough

There is a tendency in modelling culture to fear noisy labels more than slow labels.

In practice both matter, and the trade can run either way.

If the cheaper readout is biased beyond usefulness, fine, do not build around it. But plenty of rough assays are still directionally informative enough to shape the next round. If they arrive fast and at scale, they can improve the local model before a slower perfect assay has even finished scheduling.

This is not an argument for sloppiness.

It is an argument for taking update speed seriously.

The best role for expensive experiments often comes later

None of this means expensive experiments should disappear. It means their role changes.

They become confirmatory, strategic, or decision-closing measurements rather than the first thing you buy by default. You use cheap experiments and easy chemistry to carve the space into something more intelligible, then spend heavily where the expensive readout will settle a meaningful question.

That is a far better bargain than scattering high-cost experiments across a landscape you barely understand.

Benchmark culture under-rewards this badly

A lot of public evaluation still assumes one endpoint, one dataset, one model, one score.

That misses how value is actually created when cheap experiments accelerate learning. The gain is not only better prediction accuracy on a final endpoint. The gain is earlier local adaptation, tighter assay sequencing, fewer wasted syntheses, better identification of dead regions, and a stronger model after a handful of quick cycles.

Those benefits compound. They are just awkward to summarise in one benchmark number.

Cheap does not mean low-value

This is the piece the field needs to get more comfortable saying directly.

Cheap experiments can be high-value experiments. Easy chemistry can be strategically superior chemistry. Rough early readouts can improve a programme more than pristine late ones if they arrive when the project still has room to change course.

When verification is slow and local data matter, the economics of learning stop looking like a purity contest.

They start looking like a race to update the project while the update is still worth something.

That is why cheap experiments should not be treated as a compromise.

They are often a modelling advantage.